Tubulointerstitial injury is exacerbated in streptozotocin-induced diabetic matrix metalloproteinase-2 knockout mice

链脲佐菌素诱导的糖尿病基质金属蛋白酶-2敲除小鼠肾小管间质损伤加剧

基本信息

  • 批准号:
    19590970
  • 负责人:
  • 金额:
    $ 2.75万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2007
  • 资助国家:
    日本
  • 起止时间:
    2007 至 2009
  • 项目状态:
    已结题

项目摘要

Background and Aims : Matrix metalloproteinnase-2 (MMP-2) is one of the potent metalloproteinases which can degrade various types of extracellular matrix (ECM) such as collagen IV, V and laminin. It has been suggested that diabetes-induced accumulation of ECM are, at least in part, by down-regulation of MMP-2. However there is no data whether MMP-2 activity and expression affect diabetes-induced renal damage in vivo. Therefore, we investigated the effects of MMP-2 deficiency on tubulointerstitial injury in diabetic animals.Materials and Methods : Diabetes was induced by streptozotocin (STZ)(50mg/kg) in male MMP-2 knockout mice (MMP-2 KO) and C57BL/6J mice (Ctrl). After 16 weeks, cortical MMP-2 expression and activity were measured by zymography and real-time PCR, respectively. Urinary albumin excretion (UAE) and N-acetyl-β-D-glucosaminidase (NAG) were measured by enzyme-linked immunosorbent assay (ELISA). Alfa-smooth muscle actin (α-SMA) was evaluated by western blots and immnohistoche … More mistry. Tubulointerstitial injury and fibrosis were evaluated by hematoxylin and eosin staining (HE) and Masson-trichrome staining, respectively.Results : Plasma levels of glucose and HbA1c were increased by about 2-3-folds in 16-week diabetic mice compared with non-diabetic Ctrl mice (plasma glucose ; 490.3+/-7.5mg/dl, HbA1c ; 9.91+/-0.22% in 16-week diabetic mice). MMP-2 expression and activity in the total kidney cortex of diabetic mice were increased in zymography and RT-PCR analysis. Serum levels of BUN, creatinine (Cr) and UAE were significantly increased in MMP-2 KO DM mice compared with Ctrl DM mice (BUN ; 23.2+/-1.7 vs 39.8+/-6.0mg/dl, p<0.01, Cr ; 0.07+/-0.01 vs 0.17+/-0.04mg/dl, p<0.01, UAE ; 0.08+/-0.01 vs 0.16+/-0.03mg/mgCr, p<0.05). Further, tubulointerstitial injury and cortical α-SMA expression were enhanced in DM mice, which were further increased in MMP-2 KO DM mice.Conclusions : We demonstrate for the first time that tubulointerstitial injury and fibrosis were exacerbated in diabetic MMP-2 knockout mice, even though MMP-2 levels were increased in diabetic mice. The present study suggests that the decrease in other matrix-degrading enzymes may be involved in the tubulointerstitial injury and fibrosis in diabetic nephropathy. Less
背景和目标:基质金属蛋白酶-2(MMP-2)是一种高效的金属蛋白酶,可降解各种类型的细胞外基质(ECM),如胶原IV、V和层粘连蛋白。已经表明糖尿病诱导的ECM积累至少部分是通过MMP-2的下调。但MMP-2的活性和表达是否影响糖尿病肾损害的体内研究尚未见报道。材料与方法:采用链脲佐菌素(STZ)(50 mg/kg)诱导雄性MMP-2基因敲除小鼠(MMP-2 KO)和C57 BL/6 J小鼠(Ctrl)糖尿病模型,观察MMP-2基因敲除对糖尿病大鼠肾小管间质损伤的影响。16周后,分别用酶谱法和实时荧光PCR法测定皮质MMP-2的表达和活性。采用酶联免疫吸附试验(ELISA)测定尿白蛋白排泄量(UAE)和N-乙酰-β-D-氨基葡萄糖苷酶(NAG)。免疫印迹法和免疫组化法检测α-平滑肌肌动蛋白(α-SMA)的表达 ...更多信息 mistry。结果:与非糖尿病对照组小鼠相比,16周糖尿病小鼠的血糖和HbA 1c水平升高约2-3倍(血糖:490.3+/-7.5mg/dl,HbA 1c; 9.91+/-0.22%,16周糖尿病小鼠)。酶谱分析和RT-PCR分析显示糖尿病小鼠肾皮质MMP-2表达和活性增加。MMP-2敲除DM小鼠血清BUN、Cr和UAE水平显著高于对照DM小鼠(BUN ; 23.2+/-1.7 vs 39.8+/-6.0mg/dl,p<0.01,Cr ; 0.07+/-0.01 vs 0.17+/-0.04mg/dl,p<0.01,UAE ; 0.08+/-0.01 vs 0.16+/-0.03mg/mgCr,p<0.05)。此外,肾小管间质损伤和皮质α-SMA表达在DM小鼠中增强,在MMP-2 KO DM mice中进一步增加。结论:我们首次证明糖尿病MMP-2敲除小鼠中肾小管间质损伤和纤维化加剧,即使MMP-2水平在糖尿病小鼠中增加。本研究提示,其他基质降解酶的减少可能参与了糖尿病肾病肾小管间质损伤和纤维化。少

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Possible involvument of AGE and MMP-2 in podocyte detachment and loss
AGE 和 MMP-2 可能参与足细胞脱离和丢失
Circulating Matrix Metalloproteinase-2 Is an Independent Correlate of Proteinuria in Patients with Chronic Kidney Disease
  • DOI:
    10.1159/000151439
  • 发表时间:
    2009-01-01
  • 期刊:
  • 影响因子:
    4.2
  • 作者:
    Nagano, Makio;Fukami, Kei;Okuda, Seiya
  • 通讯作者:
    Okuda, Seiya
Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway.
NADPH 氧化酶的抑制可通过蛋白激酶 C-α 依赖性途径预防糖尿病肾病中晚期糖基化终产物介导的损伤。
  • DOI:
  • 发表时间:
    2008
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Thallas-Bonke V;Thorpe SR;Coughlan MT;Fukami K;Yap FY;Sourris KC;Penfold SA;Bach LA;Cooper ME
  • 通讯作者:
    Cooper ME
Possible involvement of AGE and MMP-2 in podocyte detachment and loss.
AGE 和 MMP-2 可能参与足细胞脱离和丢失。
  • DOI:
  • 发表时间:
    2008
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Kei Fukami;Sho-ichi Yamagishi;Seiji Ueda;Seiya Okuda;Fukami K
  • 通讯作者:
    Fukami K
Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGES (RAGE) expression
  • DOI:
    10.1016/j.mvr.2007.05.001
  • 发表时间:
    2008-01-01
  • 期刊:
  • 影响因子:
    3.1
  • 作者:
    Yamagishi, Sho-ichi;Matsui, Takanori;Imaizumi, Tsutomu
  • 通讯作者:
    Imaizumi, Tsutomu
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

FUKAMI Kei其他文献

FUKAMI Kei的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('FUKAMI Kei', 18)}}的其他基金

Novel therapeutic approach against receptor for advanced glycation end products in patients with diabetic nephropathy or RPGN.
针对糖尿病肾病或 RPGN 患者晚期糖基化终末产物受体的新治疗方法。
  • 批准号:
    22590904
  • 财政年份:
    2010
  • 资助金额:
    $ 2.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Vwdeを基軸とした細胞外基質が担う核心的蛋白情報ネットワーク網の解明
阐明以Vwde为中心的细胞外基质所发挥的核心蛋白质信息网络
  • 批准号:
    24K20053
  • 财政年份:
    2024
  • 资助金额:
    $ 2.75万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ヒト角膜内皮疾患における細胞外基質の非一様化に対する内皮細胞の応答機構の解明
阐明人角膜内皮疾病中内皮细胞对细胞外基质不均匀性的反应机制
  • 批准号:
    23K28399
  • 财政年份:
    2024
  • 资助金额:
    $ 2.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
マクロファージの表現型に影響する細胞外基質ラミニンの機能解析
影响巨噬细胞表型的细胞外基质层粘连蛋白的功能分析
  • 批准号:
    23K24517
  • 财政年份:
    2024
  • 资助金额:
    $ 2.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
細胞外基質環境下でCD73-CXCL10経路が腫瘍自己制御機構に果たす役割の解明
阐明CD73-CXCL10通路在细胞外基质环境中肿瘤自身调节中的作用
  • 批准号:
    24K13110
  • 财政年份:
    2024
  • 资助金额:
    $ 2.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
微小細胞外基質を用いた細胞動態と遺伝子発現の統合解析による再発転移機構の解明
使用微细胞外基质对细胞动力学和基因表达进行综合分析,阐明复发转移机制
  • 批准号:
    24K18529
  • 财政年份:
    2024
  • 资助金额:
    $ 2.75万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
細胞外基質ECM1を標的とした新たな皮膚癌間質標的治療へのアプローチ
一种针对细胞外基质 ECM1 的皮肤癌基质靶向治疗新方法
  • 批准号:
    24K11489
  • 财政年份:
    2024
  • 资助金额:
    $ 2.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
ヒト角膜内皮疾患における細胞外基質の非一様化に対する内皮細胞の応答機構の解明
阐明人角膜内皮疾病中内皮细胞对不均匀细胞外基质的反应机制
  • 批准号:
    23H03710
  • 财政年份:
    2023
  • 资助金额:
    $ 2.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
脂肪細胞分化調節における細胞外基質の硬さ環境の記憶形成機構の解明
阐明细胞外基质硬度环境调节脂肪细胞分化的记忆形成机制
  • 批准号:
    22K14861
  • 财政年份:
    2022
  • 资助金额:
    $ 2.75万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
下肢動脈石灰化病変形成機序における細胞外基質代謝および炎症の関与
细胞外基质代谢及炎症参与下肢动脉钙化病变形成机制
  • 批准号:
    22K16149
  • 财政年份:
    2022
  • 资助金额:
    $ 2.75万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
脳小血管の細胞外基質の摂動を起こす細胞群の同定と、その制御機構の解読
识别引起小脑血管细胞外基质扰动的细胞群并破译其控制机制
  • 批准号:
    22H00466
  • 财政年份:
    2022
  • 资助金额:
    $ 2.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了